GLP1R and intestinal obstruction: A recent publication from JAMA on the analysis of people who have been taking GLP-1 agonists from 2006 to 2020 shows that people who are taking GLP-1 agonists have a nine-fold higher risk of developing acute pancreatitis compared with the older drug for weight loss, bupropion, and four times more frequent intestinal obstruction and three times more frequent gastroparesis.